Pharmaceutical Supply – Prednisolone Acetate Ophthalmic Suspension

The contract pertains to the supply and delivery of one bottle of sterile Prednisolone Acetate Ophthalmic Suspension under a Defense Logistics Agency delivery order, intended for use within the Department of Defense healthcare system. The product must fully comply with FDA regulations, USP <797> standards for sterile compounding, and all DLA logistical and quality control requirements to ensure safety and efficacy for ophthalmic administration. The item is classified under NAICS code 325412, indicating pharmaceutical manufacturing, and is delivered under a subcontract arrangement with no set-aside provisions. All performance obligations are tied to DLA’s procurement and logistics protocols, with delivery governed by the specified contract and delivery order numbers. The procurement is managed through DLA’s official systems and is linked to a specific delivery requirement, though the place of performance and point of contact details are not provided. The solicitation was posted on August 9, 2026, and the transaction is part of routine defense medical supply chain operations, ensuring timely availability of a critical ophthalmic medication under strict regulatory and quality assurance frameworks.